Compare Stocks

Wells Fargo lowered the firm’s price target on Alumis (ALMS) to $18 from $25 and keeps an Overweight rating on the shares. Following the LUMUS results, Alumis’ re-rating depends entirely

H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Alumis (ALMS) to $9 from $15 and keeps a Buy rating on the shares. The firm believes the market

“Each additional readout from the ONWARD program has strengthened the consistent body of evidence supporting envudeucitinib’s highly competitive profile in moderate-to-severe plaque psoriasis,” said Martin Babler, President and Chief Executive

Alumis Inc. ($ALMS) announced an update on their ongoing clinical study. The ONWARD1 Phase 3 study from Alumis Inc. aims to test if ESK-001 can safely improve moderate to severe

Alumis Inc. ($ALMS) announced an update on their ongoing clinical study. Alumis Inc. (ALMS) has completed a key Phase 3 study called “A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator

Alumis (ALMS) announced new envudeucitinib data from the ONWARD Phase 3 clinical program-ONWARD1, ONWARD2, and the long-term extension ONWARD3. The results, presented at the 26th Annual Fall Clinical Dermatology Conference,

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Alumis Inc. today and set a price target of $15.00. Mitchell Kapoor has given his Buy rating due to a

Guggenheim downgraded Alumis (ALMS) to Neutral from Buy without a price target after the Phase IIb study evaluating envudeucitinib in systemic lupus erythematosus missed both primary and secondary endpoints in

Alumis (ALMS) is up 10.7%, or $1.01 to $10.48. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on

The major averages were broadly higher, rebounding a little from yesterday’s declines as investors continue to react to escalating tensions between the U.S. and Iran, rising oil prices, and a